Artificial intelligence is transforming industries with independent reasoning and complex workflow orchestration. New AI products are drivi...

Kazakhstan's ambassador expressed keen interest in expanding business engagement with West Bengal. The nation views West Bengal as a crucia...

PAG acquired a controlling stake in Acme Formulation for $145 million (?1,054 crore) through its PAG Asia III buyout fund in 2021. Founder ...

Sakar Healthcare announced a substantial net profit increase for the first quarter of 2026-27. The company's revenue from operations also s...

The threat of a US tariff on Indian pharma is no longer a vague fear; or at least that is what President Trump wants us to believe. There i...

Pharma mutual funds are leading returns in CY2026, driven by strong earnings, defensive demand, and US export growth. Despite recent outper...

US pharma tariffs: Experts have urged a shift towards global diversification and prioritising innovation for Indian pharma to lessen market...

Cipla reported a 39% drop in net profit to ₹789 crore for the June quarter due to weakness in its North America business and margin compres...

Akums Drugs and Pharmaceuticals will acquire Oriflame India's manufacturing business. This significant deal is valued at fifty-six crore ru...

Indian drug shares declined Wednesday following US President Trump's tariff announcement. These proposed tariffs will significantly impact ...

The healthcare sector anticipates strong growth in domestic formulations and emerging markets. Companies with less US generics dependence w...

Donald Trump's announcement of tariffs of up to 200% on pharmaceutical imports triggered a selloff in Indian pharma stocks. However, analys...

US President Donald Trump's proposed tariffs of up to 200% on imported generic medicines could put pressure on India's pharmaceutical expor...

President Donald Trump has given generic drugmakers two years to shift manufacturing to the US or face 100% import tariffs from August 2028...

Trump's generic drug tariffs plan provides Indian drugmakers a two-year duty-free window. This allows companies time to reassess manufactur...

For Indian exporters, the two-year tariff-free period offers additional time to reassess supply chains and investment plans. While the imme...

Pharma stocks, including Sun Pharma, Cipla, Lupin and Dr Reddy's, fell up to 2.5% after US President Donald Trump announced a phased tariff...